Mithrl has announced a $20 million Series A, led by Obvious Ventures, with participation from Headline, AGI House, and several pharmaceutical executives. The announcement brings up an increasingly important challenge in...read more
Category - Emerging technologies/applications
How AI Language Models Are Uncovering Hidden Bacterial Immune Systems
How artificial intelligence is revealing thousands of previously unknown bacterial antiviral defense systems, and why they could become the next generation of biotechnology tools TL;DR: Two recently published science...read more
Tempus Acquires Personalis and Raises the Stakes in the MRD Market
The acquisition combines Personalis’s highly sensitive molecular residual disease (MRD) technology with Tempus’s commercial reach, multimodal data, and AI-enabled precision-oncology platform. TL;DR: Tempus AI’s proposed...read more
DNA Origami used to build novel vaccines
Image credit: Bannard and Howarth. (2026) Despite the current public image challenges surrounding vaccines, progress in basic science and application continues to advance rapidly. A particularly significant...read more
